Preliminary findings from the Gynecologic Oncology Group’s (GOG) GOG 213 study show an improvement in overall survival for women with ovarian cancer when bevacizumab is added to standard chemotherapy. The researchers report overall survival was a median 5 months longer for women who received chemotherapy plus bevacizumab than for women who received chemotherapy alone. These findings were presented at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer.
Median overall survival for women in the chemotherapy plus bevacizumab group was 42.2 months, compared with 37.3 months in the group who received chemotherapy alone. The additional drug improved progression-free survival by nearly 3.5 months (13.8 months for chemotherapy plus bevacizumab vs 10.4 months for chemotherapy alone). The ongoing study will assess quality of life in the women who also received bevacizumab and the role of secondary surgery before chemotherapy.
Preliminary findings from the Gynecologic Oncology Group’s (GOG) GOG 213 study show an improvement in overall survival for women with ovarian cancer when bevacizumab is added to standard chemotherapy.
In a study presented at a meeting of women’s cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.
Enjoying our content?
Thanks for visiting Oncology Nurse Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Oncology Nurse Advisor. Register for free and gain unlimited access to:
- Clinical Updates
- Evidence-Based Guidance
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.